HomeCompareLAAC vs MRK

LAAC vs MRK: Dividend Comparison 2026

LAAC yields 72.99% · MRK yields 2.76%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 LAAC wins by $1.15M in total portfolio value
10 years
LAAC
LAAC
● Live price
72.99%
Share price
$2.74
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$1.21M
Annual income
$326,872.01
Full LAAC calculator →
MRK
Merck & Co. Inc.
● Live price
2.76%
Share price
$120.31
Annual div
$3.32
5Y div CAGR
32.7%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$56.8K
Annual income
$9,798.13
Full MRK calculator →

Portfolio growth — LAAC vs MRK

📍 LAAC pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodLAACMRK
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, LAAC + MRK cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
LAAC pays
MRK pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

LAAC
Annual income on $10K today (after 15% tax)
$6,204.38/yr
After 10yr DRIP, annual income (after tax)
$277,841.21/yr
MRK
Annual income on $10K today (after 15% tax)
$234.56/yr
After 10yr DRIP, annual income (after tax)
$8,328.41/yr
At 15% tax rate, LAAC beats the other by $269,512.80/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of LAAC + MRK for your $10,000?

LAAC: 50%MRK: 50%
100% MRK50/50100% LAAC
Portfolio after 10yr
$632.3K
Annual income
$168,335.07/yr
Blended yield
26.62%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on MRK right now

LAAC
Analyst Ratings
1
Buy
Consensus: Buy
Price Target
$5.08
+85.4% upside vs current
Range: $3.50 — $7.50
Altman Z
0.2
Piotroski
4/9
MRK
Analyst Ratings
25
Buy
11
Hold
1
Sell
Consensus: Buy
Price Target
$128.54
+6.8% upside vs current
Range: $100.00 — $150.00
Altman Z
4.0
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

LAAC buys
0
MRK buys
0
No recent congressional trades found for LAAC or MRK in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricLAACMRK
Forward yield72.99%2.76%
Annual dividend / share$2.00$3.32
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%32.7%
Portfolio after 10y$1.21M$56.8K
Annual income after 10y$326,872.01$9,798.13
Total dividends collected$1.04M$28.9K
Payment frequencyquarterlyquarterly
SectorStockHealthcare
Analyst consensusBuyBuy
Analyst price target$5.08$128.54

Year-by-year: LAAC vs MRK ($10,000, DRIP)

YearLAAC PortfolioLAAC Income/yrMRK PortfolioMRK Income/yrGap
1← crossover$17,999$7,299.27$11,206$366.19+$6.8KLAAC
2$31,538$12,278.65$12,650$502.35+$18.9KLAAC
3$53,852$20,106.86$14,407$694.19+$39.4KLAAC
4$89,709$32,087.28$16,585$967.82+$73.1KLAAC
5$145,944$49,955.34$19,342$1,363.89+$126.6KLAAC
6$232,114$75,953.49$22,913$1,947.19+$209.2KLAAC
7$361,258$112,895.84$27,662$2,823.89+$333.6KLAAC
8$550,760$164,213.98$34,159$4,173.35+$516.6KLAAC
9$823,289$233,976.05$43,337$6,308.80+$780.0KLAAC
10$1,207,791$326,872.01$56,776$9,798.13+$1.15MLAAC

LAAC vs MRK: Complete Analysis 2026

LAACStock

Lithium Americas (Argentina) Corp. operates as a resource company. The company explores for lithium deposits. It owns interests in the Cauchari-Olaroz project located in Jujuy province of Argentina; and Pastos Grandes project located in the Salta province of Argentina. Lithium Americas (Argentina) Corp. is headquartered in Vancouver, Canada.

Full LAAC Calculator →

MRKHealthcare

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Ridgeback Biotherapeutics; and Gilead Sciences, Inc. to jointly develop and commercialize long-acting treatments in HIV. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.

Full MRK Calculator →
📬

Get this LAAC vs MRK comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

LAAC vs SCHDLAAC vs JEPILAAC vs OLAAC vs KOLAAC vs MAINLAAC vs JNJLAAC vs ABBVLAAC vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.